Products

Our Products

Magle has several registered products on the market and a pipeline of highly promising projects. Arista® – owned and marketed globally for surgical hemostasis by our premium partner Davol, Inc; Spherex® – used for treatment of liver tumors by transarterial chemoembolization and marketed in Japan by Yakult Honsha and Phadebas® – used in forensic labs worldwide for the detection of biological traces. Phadebas also supports the diagnosis of pancreatitis.Starch microspheres are non-toxic, non-allergenic and metabolize into glucose. Together with excellent formulation flexibility and long-term stability, Magle’s spheres are ideal for in-vivo applications.

 

magle_products

Quantifying Alpha-Amylase

Phadebas® Amylase Test is used for both qualitative and quantitative assessment of the enzyme alpha-Amylase. The active component of Phadebas is DSM-P, microspheres in which a blue dye has been chemically bound. Alpha‑Amylase degrades the microspheres, thereby releasing the blue dye. Enzymatic activity of the tested sample is given by measuring the absorbance of the blue solution. Phadebas is used in a wide range of applications from diagnosis of pancreatitis to quality control tests for food & beverages and as a method for detecting saliva in forensic investigations.

 

For the forensic biology labs, Phadebas is also available with the DSM-P reagent immobilised on filter paper, Phadebas Forensic Press Test. In 2010 Magle launched a new product in the Phadebas family, Phadebas Honey Diastase test. All Phadebas products are marketed and sold worldwide in Magle’s own name or through distributors. For additional information and ordering, please visit www.phadebas.com

Trans-arterial Chemoembolisation for the treatment of primary Hepatocellular Carcinoma

Spherex® is registered as a medical device in Japan, where it is marketed by Yakult Honsha. The active component, DSM-S microspheres, sterilised and suspended in saline solution, is produced by Magle.

DSM-S is administered via a catheter into the hepatic artery where it forms an occlusion in the vessel tree. Co-administered with a cytostatic drug, it helps to achieve markedly higher local levels of the drug and much less side effects due to reduced systemic circulation.

Magle has acquired all rights to the product and trademark Spherex outside of Japan.

Absorbable hemostat for surgical use

Arista® AH is approved for surgical use by the FDA, European authorities, Japanese MHLW and the Chinese health authorities for in-vivo use to achieve hemostasis. The product is marketed by Magle’s premium partner Davol, Inc. Magle has developed and now produces the active component of Arista, Microporous Polysaccharide Hemospheres (MPH®). The MPH® microspheres are applied directly on the blood source where they act as hydrophilic molecular sieves.

 

MPH® thus accelerates natural hemostasis by concentrating blood platelets, proteins and red blood cells, forming a gel matrix around the particles. When applied directly to the source of bleeding, Arista®AH begins clotting the blood on contact, achieving complete hemostasis, in most cases, within minutes. The resorption process begins immediately and the microspheres are fully degraded into glucose within 2 days.

arista_front

ABSORBABLE HEMOSTAT FOR SURGICAL USE

Arista® AH is approved for surgical use by the FDA, European authorities, Japanese MHLW and the Chinese health authorities for in-vivo use to achieve hemostasis. The product is marketed by Magle’s premium partner Davol, Inc.

Magle has developed and now produces the active component of Arista, Microporous Polysaccharide Hemospheres (MPH®). The MPH® microspheres are applied directly on the blood source where they act as hydrophilic molecular sieves. MPH® thus accelerates natural hemostasis by concentrating blood platelets, proteins and red blood cells, forming a gel matrix around the particles. When applied directly to the source of bleeding, Arista®AH begins clotting the blood on contact, achieving complete hemostasis, in most cases, within minutes. The resorption process begins immediately and the microspheres are fully degraded into glucose within 2 days.

spherex

TRANS-ARTERIAL CHEMOEMBOLISATION FOR THE TREATMENT OF PRIMARY HEPATOCELLULAR CARCINOMA

Spherex® is registered as a medical device in Japan, where it is marketed by Yakult Honsha. The active component, DSM-S microspheres, sterilised and suspended in saline solution, is produced by Magle.

DSM-S is administered via a catheter into the hepatic artery where it forms an occlusion in the vessel tree. Co-administered with a cytostatic drug, it helps to achieve markedly higher local levels of the drug and much less side effects due to reduced systemic circulation.

Magle has acquired all rights to the product and trademark Spherex outside of Japan.